Last updated: March 14, 2026

Definition

Hirudotherapy (from Latin hirudo, meaning leech) is the therapeutic application of live medicinal leeches to human tissue for medical purposes. The practice involves placing Hirudo medicinalis, H. verbana, or H. orientalis on or near affected tissue, where the leech attaches, feeds on blood, and simultaneously delivers a complex cocktail of bioactive salivary compounds into the patient’s tissue.

Key Distinctions

Hirudotherapy ≠ Bloodletting

Unlike historical phlebotomy (venesection), hirudotherapy’s therapeutic value comes primarily from the bioactive saliva delivered during feeding — not from blood removal itself. The mechanical decongestive effect is important in surgical contexts, but the pharmacological effects distinguish modern hirudotherapy from ancient bloodletting practices.

Medical Device, Not Drug

In the United States, medicinal leeches are regulated as FDA 510(k)-cleared medical devices, not drugs or biologics. As a pre-amendment device (marketed before the 1976 Medical Device Amendments), medicinal leeches have not been formally assigned a device classification (Class I, II, or III) through rulemaking. They require 510(k) premarket notification—the same regulatory pathway used for Class II devices. This governs how they are manufactured, distributed, marketed, and used in clinical settings.

Global Practice Context

Hirudotherapy is practiced worldwide with varying regulatory frameworks. In Germany and Russia, it is an established complementary therapy covered by some insurance plans and practiced by trained physicians and naturopaths. In India, it is part of traditional Ayurvedic medicine (Jalaukavacharana) with government recognition. In the United States, use is primarily limited to surgical/hospital settings under the FDA device framework, with growing interest in outpatient applications for musculoskeletal conditions.

FDA Regulatory Status

FDA-Cleared Indication

FDA-Cleared Medical Device. Medicinal leeches are cleared under 510(k) K040187 (Product Code NRN) for relief of venous congestion due to impaired venous drainage following surgical procedures.

Regulatory History

Date	Event	Detail
June 2004	510(k) K040187 cleared	First FDA 510(k) clearance for medicinal leeches (Ricarimpex SAS)
February 2014	510(k) K132958 cleared	Clearance for Biopharm Leeches (UK)
August 2015	510(k) K140907 cleared	Clearance for Carolina Biological Supply Co.

Device Classification

510(k)-Cleared Medical Device
Product Code: NRN
Regulation: 21 CFR Part 820 (QMSR)

Cleared Indication

Relief of venous congestion in compromised tissue flaps and grafts following microsurgical procedures where venous insufficiency is present

Cleared Suppliers

Carolina Biological Supply Co. (primary US supplier) and Biopharm Leeches (UK, international). Only FDA-cleared sources should be used clinically.

510(k) Clearance Explained

A 510(k) clearance means the FDA has determined that the device is substantially equivalent to a legally marketed predicate device. Unlike premarket approval (PMA), 510(k) does not require the manufacturer to submit clinical trial data demonstrating efficacy. The clearance establishes that the device is substantially equivalent to a predicate device for its cleared indication based on comparison to existing devices. This is a lower regulatory bar than PMA approval required for Class III devices.

Off-Label Use

The FDA clearance is specific to venous congestion in surgical contexts. All other clinical uses discussed on this website represent off-label application. Off-label use is legal and common in medicine, but requires institutional governance, informed consent explicitly addressing the off-label nature, and clinical documentation of the evidence-based rationale.

Mechanisms of Action

Medicinal leech therapy produces therapeutic effects through three interrelated mechanisms: mechanical blood removal, delivery of bioactive salivary compounds, and secondary physiological responses.

Mechanical Blood Removal

The leech attaches using its posterior sucker for stability and anterior sucker for feeding. The tripartite jaw (three jaw blades arranged in a Y-pattern) creates a characteristic Y-shaped incision and the pharyngeal pump extracts blood:

Phase	Volume	Duration	Clinical Significance
Active feeding	5-15 mL per leech	20-60 minutes	Immediate decompression, salivary compound delivery
Passive bleeding	50-150 mL per site	4 to 24 hours	Sustained decompression, ongoing anticoagulant effect
Total per session	55-165 mL per leech	Up to 24 hours total	Cumulative with multiple leeches; hemoglobin monitoring required

In venous congestion, the mechanical removal of blood reduces interstitial pressure from 30-40 mmHg (congested) toward the normal range of 10-15 mmHg, restoring the arteriovenous pressure gradient necessary for tissue perfusion. With multiple leeches applied serially (2-6 per session, every 4-8 hours), the cumulative blood loss can be significant — some patients require transfusion support, particularly during prolonged courses.

Salivary Pharmacology

The leech SGSry system delivers 434+ identified proteins (Liu et al., 2019) with diverse pharmacological activities. The major therapeutic compounds include:

Compound	Mechanism	Clinical Relevance	Duration
Hirudin (~7 kDa)	Direct thrombin inhibitor; binds active site + exosite I	Prevents local clot formation; maintains wound bleeding for sustained decompression	Local: 24-48h; systemic: minimal
Calin (~65 kDa)	Inhibits platelet adhesion to collagen and vWF	Prolongs bleeding time; prevents microvascular thrombosis in injured tissue	12-24h local effect
Hyaluronidase (~60 kDa)	Degrades hyaluronic acid in extracellular matrix	Increases tissue permeability; enhances penetration of other salivary compounds	Hours; enables deeper compound diffusion
Eglin c (~8 kDa)	Inhibits neutrophil elastase, cathepsin G, chymase	Reduces inflammatory tissue damage; protects extracellular matrix from enzymatic degradation	Hours; local anti-inflammatory
Destabilase (~12 kDa)	Isopeptidase cleaving ε(γ-Glu)-Lys bonds in stabilized fibrin	Fibrinolytic activity dissolves existing microthrombi; also has antimicrobial properties	Hours; unique mechanism
Acetylcholine + Histamine-like	Vasodilation via muscarinic and H1/H2 receptors	Local vasodilation improves microcirculation; contributes to characteristic erythema around bite site	Minutes to hours

Immunomodulatory Effects

Emerging research suggests leech SGS modulates the local immune response beyond simple anti-inflammatory effects. Complement system activation, cytokine modulation (particularly IL-6 and TNF-α reduction), and effects on macrophage polarization have been observed in vitro. These immunomodulatory properties may contribute to the anti-inflammatory and wound-healing effects observed clinically, though the in vivo significance and mechanisms remain under investigation.

Neurological Effects

Patients consistently report that leech bites are less painful than expected, suggesting local anesthetic properties. The mechanism is not fully characterized but may involve: (1) TRPV1 receptor modulation reducing nociceptive signaling, (2) local vasodilation reducing tissue pressure on nerve endings, and (3) counter-irritation effects consistent with gate control theory. Some investigators have proposed that the endorphin release triggered by the controlled tissue injury may contribute to the analgesic effects reported in musculoskeletal applications.

Typical Treatment Session

While protocols vary by institution and indication, a typical leech therapy session follows a standardized sequence:

Pre-Treatment

Patient Preparation

• Informed consent (including off-label status if applicable)
• Baseline labs: CBC, coagulation panel
• Allergy screening (leech components, antibiotics)
• Antibiotic prophylaxis initiated (ciprofloxacin 500mg or TMP-SMX DS)
• Application area cleaned, dried (no alcohol/antiseptic residue)
• Type and screen for potential transfusion

Leech Preparation

• Verify FDA-cleared supplier documentation
• Inspect leeches for activity (vigorous swimming, rapid response)
• Select 2-6 leeches depending on area size
• Brief rinse in sterile saline
• Prepare containment barrier to prevent migration

Application & Monitoring

Phase	Duration	Nursing Actions
Attachment	1-5 minutes	Place leech on target area; guide with moist gauze if needed. A small pinprick near the target may encourage attachment.
Active feeding	20-60 minutes	Monitor leech (body swelling indicates feeding). Do NOT pull off — allow natural detachment. Check containment barrier.
Detachment	Spontaneous at satiation	Dispose in alcohol or formalin. NEVER reuse. Place in biohazard waste. Apply loose absorbent dressing to bite site.
Post-detachment bleeding	4 to 24 hours	Expected and therapeutically beneficial. Change dressings as needed. Monitor hemoglobin q6-8h. Quantify blood loss.

Patient Experience

Most patients report the leech bite as a mild pinching or stinging sensation lasting 1-2 minutes, followed by numbness at the bite site as salivary anesthetics take effect. The most common patient concerns are psychological (aversion to the leech itself) rather than physical discomfort. Post-detachment, the bite site may itch for 1-2 weeks as it heals. The characteristic Y-shaped wound typically heals within 2-4 weeks, sometimes leaving a small scar.

Key Safety Points

Never forcibly remove an attached leech — this can cause the jaws to remain in the wound. If removal is necessary before natural detachment, apply salt or alcohol to the leech body. Post-treatment monitoring should include hemoglobin checks (q6-8h during active treatment), wound site inspection for infection signs, and assessment for systemic allergic reactions.

Off-Label and Investigational Uses

Beyond the FDA-cleared indication, hirudotherapy has been investigated in various clinical contexts. Evidence quality varies substantially:

Knee Osteoarthritis

Strongest off-label evidence. Multiple RCTs (Michalsen 2003, Andereya 2008) show significant pain reduction (WOMAC, DASH) at 4-12 weeks. Comparable to topical diclofenac in direct comparison. See Osteoarthritis Evidence.

Chronic Venous Insufficiency

Moderate evidence for improvement in edema, pain, and skin changes. Theoretical rationale is strong (anticoagulant + anti-inflammatory effects on venous wall pathology). See CVI Evidence.

Wound Healing

Growing evidence for chronic wounds including diabetic and venous ulcers. Multi-mechanism rationale: debridement, antimicrobial, anti-inflammatory, and microcirculation improvement. See Wound Healing Evidence.

Pain Syndromes

Limited evidence for low back pain, epicondylitis, and other conditions. Blinding is a major methodological challenge. Evidence level comparable to acupuncture. See Pain Evidence.

Important Notice

Off-label uses require institutional governance, informed consent explicitly addressing the off-label nature of treatment, and clinical documentation of the evidence-based rationale. Evidence quality varies; see condition-specific evidence pages for detailed summaries.

Hirudotherapy vs. Alternative Decongestive Approaches

For the FDA-cleared indication (venous congestion in tissue flaps), several alternative or complementary approaches exist:

Approach	Mechanism	Advantages	Limitations
Medicinal Leeches	Mechanical + pharmacological	Bioactive saliva, sustained bleeding, proven efficacy	Infection risk (Aeromonas), blood loss, patient aversion
Surgical Revision	Re-anastomosis of venous outflow	Definitive fix if successful	Technically demanding, often impossible (no suitable vein), second surgery risk
Heparin-Soaked Pledgets	Local anticoagulation from wound surface	No infection risk, no patient aversion	Limited to surface application, lacks bioactive compounds, less effective decompression
Mechanical Leech Devices	Vacuum-assisted blood extraction	No infection risk, controllable, less patient aversion	No bioactive saliva, requires heparin addition, limited clinical validation
Chemical Leeching	Stab incisions + topical heparin	Immediately available, no supply issues	Requires repeated stab incisions, no bioactive compounds, labor-intensive

Despite available alternatives, biological leeches remain preferred in many microsurgery centers because the combination of mechanical decompression and pharmacological effects (anticoagulation, vasodilation, anti-inflammation) is difficult to replicate with any single alternative approach. The ongoing post-detachment bleeding provides sustained decompression that mechanical methods require continuous intervention to achieve.

Historical Context

Medicinal leech therapy has one of the longest continuous histories of any medical intervention, spanning over 3,500 years across multiple civilizations.

The earliest evidence appears in Egyptian tomb paintings (~1500 BCE). In India, the Sushruta Samhita (~800 BCE) systematically described leech therapy (Jalaukavacharana) as part of Panchakarma detoxification. Greek and Roman physicians including Nicander, Pliny, and Galen incorporated leeches into humoral medicine.

The 19th century saw both the peak and nadir of leech use. Broussais’ leech mania (1820s-1850s) consumed 35-40 million leeches annually in France alone, nearly driving H. medicinalis to extinction. The subsequent collapse of humoralism discredited leech therapy for nearly a century.

The modern revival began with Derganc and Zdravic’s 1960 publication on leech use in plastic surgery, followed by increasing adoption in microsurgical salvage through the 1970s-1990s. The 2004 FDA clearance established medicinal leeches as legitimate medical devices in the United States, and today they are standard of care for flap salvage in many academic medical centers. For detailed history, see our History of Medicinal Leech Therapy page.

Training and Credentialing

There is currently no formal U.S. certification for hirudotherapy practitioners. Competency requirements vary by institution:

Typical Competency Requirements

• Understanding of indications and contraindications
• Leech handling and application technique
• Post-application monitoring protocols
• Bleeding management and transfusion criteria
• Infection prevention and antibiotic prophylaxis
• Adverse event recognition and management
• Documentation requirements

International Programs

Germany, Russia, and India have more formalized training programs, including multi-day certification courses for physicians and naturopaths. The American Society of Hirudotherapy aims to develop evidence-based educational resources and, eventually, competency standards for U.S. practitioners. CME-pathway planning is underway.

Key Takeaways

✅ FDA-cleared: 510(k)-cleared medical devices for venous congestion in surgical flaps/grafts (K040187)
✅ Multi-mechanism therapy: Mechanical blood removal + 434+ bioactive salivary compounds
✅ Standard of care: Flap salvage in plastic/reconstructive surgery at many centers
⚠️ Off-label uses: Require institutional governance, informed consent, and evidence-based rationale
⚠️ Safety monitoring: Aeromonas prophylaxis, bleeding management, and hemoglobin monitoring required
🔬 Active research: Growing evidence base for osteoarthritis, wound healing, and other conditions

Medical Advice Disclaimer

This page provides educational information about hirudotherapy and does not constitute medical advice. If you are considering leech therapy, consult a qualified healthcare provider who can evaluate your specific clinical situation.

What Is Hirudotherapy?